Related Experiment Video

Updated: Apr 26, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.6K

Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung

Johanna N Spaans1, Glenwood D Goss2

  • 1Ottawa Hospital Research Institute , Ottawa, ON , Canada.

Frontiers in Oncology
|August 8, 2014
PubMed

Insights

Targeted therapies for lung cancer show promise but are limited by drug resistance in patients with specific genetic mutations. This review examines resistance mechanisms to epidermal growth factor receptor and anaplastic lymphoma kinase inhibitors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Targeting oncogenic alterations has advanced lung cancer management.
  • Molecularly targeted therapies offer significant clinical benefits.
  • Current targeted treatments are primarily effective for specific genetic mutations.

Purpose of the Study:

  • To review primary and secondary drug resistance in lung cancer.
  • To examine limitations of current targeted therapies.
  • To discuss the impact of resistance on patient management.

Main Methods:

  • Literature review of targeted therapies for lung cancer.
  • Focus on tyrosine kinase inhibitors targeting epidermal growth factor receptor (EGFR).
  • Analysis of resistance mechanisms for anaplastic lymphoma kinase (ALK) rearrangements.

Main Results:

  • Therapeutic efficacy of targeted therapy is often limited to patients with specific mutations.
  • Drug resistance, both primary and secondary, is a significant challenge.
  • Short-lived therapeutic benefits are common.

Conclusions:

  • Understanding drug resistance is crucial for improving lung cancer treatment.
  • Limitations in targeted therapies necessitate further research.
  • Developing strategies to overcome resistance is essential for long-term patient management.
Keywords:
EGFRacquired resistanceinhibitionmolecular biologyprimary resistance

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.0K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

12.8K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
80
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K